A distinguished healthcare leader, Michael Dale currently serves as President, Chief Executive Officer and member of the Board of Directors for Axogen, Inc. (NASDAQ: AXGN), a global leader dedicated to the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
As an accomplished medical device executive, Mr. Dale has over 35 years of experience leading transformative, high-technology medical device companies in the cardiovascular, neuromodulation, diabetes and electrophysiology markets. His past executive leadership roles span both public and private medical device companies, including Abbott Structural Heart, GI Dynamics, Helical Solutions, ATS Medical, Endocardial Solutions, Cyberonics, St. Jude Medical and American Edwards Laboratories.
Mr. Dale has been an active director and advisor, serving on the boards of Preceptis Medical, Enpath Medical, Rhythmia Medical, Neuronetics, Inc., NeoChord, the Advanced Medical Technology Association (AdvaMed), the St. Mary’s University Council of Regents for the School of Graduate and Professional Programs, and the University of Minnesota Carlson School of Management Medical Industry Leadership Institute. At present, he serves on the advisory board of Purdue University’s Weldon School of Biomedical Engineering, and California Polytechnic State University’s Center for Innovation & Entrepreneurship as Student Mentor.
Mr. Dale holds a Bachelor of Science degree from California Polytechnic State University in San Luis Obispo, California.
What is Michael D. Dale's net worth?
The estimated net worth of Michael D. Dale is at least $3.10 million as of December 9th, 2025. Dale owns 88,537 shares of AxoGen stock worth more than $3,099,680 as of February 3rd. This net worth evaluation does not reflect any other assets that Dale may own. Learn More about Michael D. Dale's net worth.
How do I contact Michael D. Dale?
Has Michael D. Dale been buying or selling shares of AxoGen?
Michael D. Dale has not been actively trading shares of AxoGen during the last ninety days. Most recently, Michael D. Dale sold 61,463 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $31.21, for a transaction totalling $1,918,260.23. Following the completion of the sale, the chief executive officer now directly owns 88,537 shares of the company's stock, valued at $2,763,239.77. Learn More on Michael D. Dale's trading history.
Who are AxoGen's active insiders?
AxoGen's insider roster includes Marc Began (EVP), P Burke (Director), Michael Dale (CEO), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Lindsey Hartley (CFO), John Johnson (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Paul Thomas (Director), Joseph Tyndall (Director), Kathy Weiler (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.
Are insiders buying or selling shares of AxoGen?
In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 475,453 shares worth more than $12,603,234.48. The most recent insider tranaction occured on December, 16th when Director Amy Mcbride Wendell sold 43,684 shares worth more than $1,280,378.04. Insiders at AxoGen own 2.8% of the company.
Learn More about insider trades at AxoGen. Information on this page was last updated on 12/16/2025.